Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Experimental hematology - 1 Nov 2007

Williams Donna M, Kim Ann H, Rogers Ophelia, Spivak Jerry L, Moliterno Alison R

Abstract excerpt

OBJECTIVE: The chronic myeloproliferative disorders (MPD), polycythemia vera (PV), essential thrombocytosis, and idiopathic myelofibrosis (IMF), are characterized by a spectrum of clinical features and linked by common genetic lesions in JAK2 and MPL. However, the clinical phenotypes in genetically undefined MPD patients are similar to those patients with JAK2 and MPL lesions. We, therefore, sought to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Polycythemia

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 17920755
DOI: 10.1016/j.exphem.2007.08.010
PMCID: PMC2149910

Genes

JAK2
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.PMID 17920755Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

Non-MPL-W515K/L mutations in myeloproliferative neoplasms: Insights from two case reports and a review of the literature.Semantic proximity Read ↗

Genotype-phenotype interactions in the myeloproliferative neoplasms.Semantic proximity Read ↗

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Semantic proximity Read ↗

JAK and MPL mutations in myeloid malignancies.Semantic proximity Read ↗

JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.Semantic proximity Read ↗

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.